Welch 1985.
Study characteristics | ||
Methods | Study design: randomised, double‐blind, placebo‐controlled Method of randomisation: not stated Exclusions post randomisation: none Losses to follow‐up: 7/147 (5%) |
|
Participants | Country: Belgium Setting: hospital Number: 147 patients Age: mean 44.5 ± 14 years active group; mean 43.6 ± 14 years placebo group Gender: 26 M:119 F Inclusion criteria: CVI with oedema and ≥ 1 related symptom Exclusion criteria: elastic stockings or compressive bandages; leg oedema from another origin; arterial insufficiency; superficial thrombophlebitis; varicose eczema or ulcer; diuretics, analgesics, steroids, NSAIDs or other venous drugs; pregnancy |
|
Interventions | Treatment: O‐(beta‐hydroxyethyl)‐rutoside 1000 mg per day Control: placebo Duration: 28 days Follow‐up: 28 days |
|
Outcomes | Primary
Secondary
|
|
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Comment: method of randomisation not given |
Allocation concealment (selection bias) | Unclear risk | Comment: method of allocation concealment not given |
Blinding (patients) | Unclear risk | Comment: no information given about methods used for blinding |
Blinding (study researchers) | Unclear risk | Comment: no information given about methods used for blinding |
Blinding (outcome assessment) | Unclear risk | Comment: no information given about methods used for blinding |
Incomplete outcome data | Low risk | Comment: number of participants in each group described, and inclusion and exclusion criteria reported as well for the most important characteristics. Number of participants who dropped out prematurely given, along with numbers of and reasons for adverse events |
Selective reporting | Low risk | Comment: protocol identified and no differences identified between protocol and article |
Other bias | Low risk | Comment: none detected |